다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Trends in pharmacological sciences, v.34 no.5, 2013년, pp.261 - 266
Hefti, F. , Goure, W.F. , Jerecic, J. , Iverson, K.S. , Walicke, P.A. , Krafft, G.A.
AI-Helper
Soluble Aβ oligomers are now widely recognized as key pathogenic structures in Alzheimer's disease. They inhibit synaptic function, leading to early memory deficits and synaptic degeneration, and they trigger the downstream neuronal signaling responsible for phospho-tau Alzheimer's pathology. T...
J. Nutr. Health Aging Grundman 17 51 2013 10.1007/s12603-013-0002-2 2012: A watershed year for Alzheimer's disease research
Exp. Neurol. Oda 136 22 1995 10.1006/exnr.1995.1080 Clusterin inhibits aggregation of β-amyloid protein and forms a soluble complex that causes oxidative stress
Proc. Natl. Acad. Sci. U.S.A. Lambert 95 6448 1998 10.1073/pnas.95.11.6448 Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins
J. Biol. Chem. Kuo 271 4077 1996 10.1074/jbc.271.8.4077 Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains
Proc. Natl. Acad. Sci. U.S.A. Gong 100 10417 2003 10.1073/pnas.1834302100 Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss
Nat. Lett. Lesne 440 352 2006 10.1038/nature04533 A specific amyloid-β protein assembly in the brain impairs memory
PLoS ONE Sehlin 7 e32014 2012 10.1371/journal.pone.0032014 Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation
Proc. Natl. Acad. Sci. U.S.A. Jin 108 5819 2011 10.1073/pnas.1017033108 Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration
Nat. Neurosci. Benilova 15 349 2012 10.1038/nn.3028 The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Nat. Struct. Mol. Biol. Ahmed 17 561 2010 10.1038/nsmb.1799 Structural conversion of neurotoxic amyloid-β1-42 oligomers to fibrils
J. Neurosci. Hillen 30 10369 2010 10.1523/JNEUROSCI.5721-09.2010 Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies
Proc. Natl. Acad. Sci. U.S.A. Hoshi 100 6370 2003 10.1073/pnas.1237107100 Spherical aggregates of amyloid β (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase-3β
J. Neurosci. Li 31 6627 2011 10.1523/JNEUROSCI.0203-11.2011 Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors
J. Biol. Chem. Stine 278 11612 2003 10.1074/jbc.M210207200 In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis
Neuropharmacology Rammes 60 982 2011 10.1016/j.neuropharm.2011.01.051 Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of amyloid β oligomers on long-term potentiation (LTP) in murine hippocampal slices
J. Neurosci. Methods Ryan 190 171 2010 10.1016/j.jneumeth.2010.05.001 An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies
Neurobiol. Aging Shughrue 31 189 2010 10.1016/j.neurobiolaging.2008.04.003 Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons
J. Neurosci. Zago 32 2696 2012 10.1523/JNEUROSCI.1676-11.2012 Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific
Methods Mol. Biol. Stine 670 13 2011 10.1007/978-1-60761-744-0_2 Preparing synthetic Aβ in different aggregation states
J. Neurochem. Barghorn 95 834 2005 10.1111/j.1471-4159.2005.03407.x Globular amyloid β-peptide1-42 oligomer - a homogeneous and stable neuropathological protein in Alzheimer's disease
J. Neurosci. Nimmrich 28 788 2008 10.1523/JNEUROSCI.4771-07.2008 Amyloid β oligomers (Aβ1-42 globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents
J. Neurochem. O’Nuallain 119 189 2011 10.1111/j.1471-4159.2011.07389.x A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ
J. Neurochem. Larson 120 Suppl. 1 125 2012 10.1111/j.1471-4159.2011.07478.x Soluble Aβ oligomer production and toxicity
Nat. Med. Klyubin 11 556 2005 10.1038/nm1234 Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo
J. Biol. Chem. Necula 282 10311 2007 10.1074/jbc.M608207200 Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct
Neurobiol. Dis. Gellerman 30 212 2008 10.1016/j.nbd.2008.01.010 Aβ-globulomers are formed independently of the fibril pathway
J. Mol. Biol. Kirkitadze 312 1103 2001 10.1006/jmbi.2001.4970 Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis
Proc. Natl. Acad. Sci. U.S.A. Bitan 100 330 2003 10.1073/pnas.222681699 Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways
J. Biol. Chem. Glabe 283 29639 2008 10.1074/jbc.R800016200 Structural classification of toxic amyloid oligomers
Neuroscience Lesne 151 745 2008 10.1016/j.neuroscience.2007.10.054 Plaque-bearing mice with reduced levels of oligomeric amyloid-β assemblies have intact memory function
Proc. Natl. Acad. Sci. U.S.A. Koffie 106 4012 2009 10.1073/pnas.0811698106 Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques
Exp. Neurol. Gaspar 223 394 2010 10.1016/j.expneurol.2009.09.001 Oligomers of amyloid β are sequestered into and seed new plaques in the brains of an AD mouse model
J. Neurosci. Cirrito 23 8844 2003 10.1523/JNEUROSCI.23-26-08844.2003 In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life
Mol. Neurodegener. Garcia-Alloza 4 19 2009 10.1186/1750-1326-4-19 Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575
PLoS Med. Jankowsky 2 e355 2005 10.1371/journal.pmed.0020355 Persistent amyloidosis following suppression of Aβ production in a transgenic model of Alzheimer disease
Acc. Chem. Res. Teplow 39 635 2006 10.1021/ar050063s Elucidating amyloid β-protein folding and assembly: a multidisciplinary approach
Biophys. J. Snyder 67 1216 1994 10.1016/S0006-3495(94)80591-0 Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths
Mol. Brain Klyubin 5 25 2012 10.1186/1756-6606-5-25 Alzheimer's disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory
J. Neurosci. Lacor 24 10191 2004 10.1523/JNEUROSCI.3432-04.2004 Synaptic targeting by Alzheimer's-related amyloid β oligomers
Neurobiol. Aging De Felice 29 1334 2008 10.1016/j.neurobiolaging.2007.02.029 Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers
J. Physiol. Townsend 572 477 2006 10.1113/jphysiol.2005.103754 Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers
J. Neurosci. Wang 24 3370 2004 10.1523/JNEUROSCI.1633-03.2004
Neurobiol. Aging Reed 32 1784 2011 10.1016/j.neurobiolaging.2009.11.007 Cognitive effects of cell-derived and synthetically derived Aβ oligomers
Neuron Hsieh 52 831 2006 10.1016/j.neuron.2006.10.035 AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss
Nat. Med. Shankar 14 837 2008 10.1038/nm1782 Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
J. Neurosci. Lacor 27 796 2007 10.1523/JNEUROSCI.3501-06.2007 Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease
J. Biol. Chem. Townsend 282 33305 2007 10.1074/jbc.M610390200 Soluble Aβ inhibits specific signal transduction cascades common to the insulin receptor pathway
Hum. Mol. Genet. Yu 21 1384 2012 10.1093/hmg/ddr576 A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines
Nat. Commun. Freir 2 336 2011 10.1038/ncomms1341 Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites
Nature Lauren 457 1128 2009 10.1038/nature07761 Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers
J. Neurosci. Barry 31 7259 2011 10.1523/JNEUROSCI.6500-10.2011 Alzheimer's disease brain-derived amyloid-β-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein
J. Neurosci. Cisse 31 10427 2011 10.1523/JNEUROSCI.1459-11.2011 Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice
Proc. Natl. Acad. Sci. U.S.A. Balducci 107 2295 2010 10.1073/pnas.0911829107 Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein
J. Neurosci. Zempel 30 11938 2010 10.1523/JNEUROSCI.2357-10.2010 Aβ oligomers cause localized Ca2+ elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines
Neurobiol. Learn. Mem. Ferreira 96 529 2012 10.1016/j.nlm.2011.08.003 The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease
FEBS J. Sakono 277 1348 2010 10.1111/j.1742-4658.2010.07568.x Amyloid oligomers: formation and toxicity of Aβ oligomers
J. Neurochem. Walsh 101 1172 2007 10.1111/j.1471-4159.2006.04426.x Aβ oligomers - a decade of discovery
Science Hardy 256 184 1992 10.1126/science.1566067 Alzheimer's disease: the amyloid cascade hypothesis
Proc. Natl. Acad. Sci. U.S.A. Georganopoulou 102 2273 2005 10.1073/pnas.0409336102 Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease
Alzheimers Dement. Wolfe 8 Suppl. 4 278 2012 10.1016/j.jalz.2012.05.746 A quantitative assay selective for amyloid oligomer species differentiates cerebrospinal fluid from Alzheimer's disease and age-matched normal
Arch. Neurol. Mehta 57 100 2000 10.1001/archneur.57.1.100 Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease
FASEB J. Fukumoto 24 2716 2010 10.1096/fj.09-150359 High-molecular-weight amyloid β oligomers are elevated in cerebrospinal fluid of Alzheimer patients
Neurology Delacourte 59 398 2002 10.1212/WNL.59.3.398 Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease
Krafft 2012 Abstracts of the 2012 Neuroscience Meeting Planner ACU-193: a drug candidate antibody selectively recognizing soluble Aβ oligomers
Look, G.C. et al. Acumen Pharmaceuticals. Methods of inhibiting the formation of amyloid-β diffusible ligands using acylhydrazide compounds, WO/2009/009768
Catalano 2012 Abstracts of the 2012 Neuroscience Meeting Planner Receptor antagonists inhibit Aβ oligomer-induced deficits
Front. Neurol. Neurosci. Giannokopoulos 24 20 2009 10.1159/000197881 Pathological substrates of cognitive decline in Alzheimer's disease
J. Alzheimers Dis. Rami 23 319 2011 10.3233/JAD-2010-101422 Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients
Clin. Interv. Aging Hansen 3 211 2008 Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis
Nat. Neurosci. Dodart 5 452 2002 10.1038/nn842 Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.